Biotech | August 02, 2021
Windlas Biotech opens for subscription this week
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Price band in the range of Rs 933 to Rs 954
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The company has already embarked upon significant expansion in Turkey
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Subscribe To Our Newsletter & Stay Updated
